Home Blog Page 1930

Osier Belle: Sydney’s Most Luxurious Outdoor Furniture Finds a New Home

By
Advertorial Desk
-

Australia’s leading bespoke outdoor furniture brand opens an expansive new showroom in Neutral Bay, redefining how Australians experience outdoor living.

SYDNEY, Oct. 20, 2025 /PRNewswire/ — After 15 years of welcoming clients to its showroom, Osier Belle, Australia’s leading designer and manufacturer of bespoke outdoor furniture, has unveiled its new, larger showroom in Neutral Bay. The move marks an exciting new chapter in the brand’s journey, reflecting both its growth and enduring commitment to delivering an exceptional client experience.

A Legacy of Craftsmanship and Vision

Founded in 2010 by Penelope Camplisson, Osier Belle has long been celebrated for reimagining outdoor living through luxurious, handcrafted designs tailored for Australian conditions. The brand new showroom in Neutral Bay represents far more than a change of address – it is a tangible expression of the brand’s vision: to create spaces that inspire, comfort and endure.

“From the beginning, my mission has been to change the way Australians view and enjoy their outdoor spaces,” says Camplisson. “Too often, outdoor furniture was either beautiful but not durable or practical but uninspiring. I wanted Osier Belle to be different, to combine meticulous craftsmanship with sophisticated design and materials that outlast the Australian climate and remain looking beautiful year after year. This new showroom allows us to showcase that vision more completely than ever.”

The showroom’s carefully curated displays immerse visitors in the world of Osier Belle, offering a glimpse into how each piece can transform a space into a sanctuary of comfort and style. Clients are invited to bring photos, dimensions and ideas, working closely with the team to create tailored solutions that perfectly fit their lifestyle and space.

The relocation also reinforces Osier Belle’s philosophy that luxury is as much about experience as it is about design. Beyond the furniture itself, clients benefit from services that extend the life and enjoyment of their pieces, including Sydney’s only in-house teak re-oiling service and white-glove delivery to ensure seamless installation.

With projects gracing some of Australia’s most prestigious homes, Osier Belle has earned a reputation not only as a furniture brand, but as a partner in crafting truly personal outdoor retreats. The new Neutral Bay showroom is designed to inspire that next chapter of creativity and collaboration with clients.

Penelope Camplisson
info@osierbelle.com.au
(02) 9949 9466
41 Military Road, Neutral Bay, NSW 2089

About Osier Belle

Osier Belle is an Australian-owned luxury outdoor furniture brand creating bespoke pieces that balance elegance, comfort and endurance. With a focus on sustainability, authenticity and timeless design, the brand continues to redefine outdoor living for homes and commercial spaces across Australia.

Recent Trade Survey Reveals

By
Advertorial Desk
-

Hong Kong’s Natural Diamond Market is on a Recovery Path


HONG KONG SAR – Media OutReach Newswire – 20 October 2025 – A recent survey indicates a positive outlook for Hong Kong’s natural diamond market, particularly with the return of tourists from Mainland China and heightened seasonal gifting demand. Over the past few years, Hong Kong’s natural diamond market has entered a phase of recalibration. This evolution reflects a complex landscape shaped by economic uncertainty, shifting consumer values, and increasing competition.

Shop photo

To better understand these dynamics, NielsenIQ, in collaboration with the Diamond Federation of Hong Kong (DFHK) and De Beers Group, conducted a natural diamond trade survey in August that included 200 respondents, comprising members of DFHK and a diverse segment of the industry, including retailers, wholesalers, and manufacturers.

Key Findings

  • Market Performance Expectations: Nearly half of the respondents anticipate positive performance in the natural diamond market over the next 12 months, while 33% expect stability.
  • Investment in Promotion: 46% of industry players plan to increase their investment in promoting natural diamonds, with 40% maintaining their current levels of investment.
  • Top Gifting Occasions: Valentine’s Day (69%), Engagement/Wedding (67%), and Christmas (59%) are expected to be the leading occasions for sales.
  • Government Support: More than half of the respondents (51%) rated the effectiveness of current government support as fair, with 68% highlighting the need for tourism campaigns to attract luxury shoppers.


Industry Trends and Practices
The survey reveals a growing emphasis on technology adoption and sustainability practices within the industry. Nearly all respondents (94%) have utilized diamond detection instruments, primarily in retail environments, while 75% have implemented sustainability initiatives such as recycling programs and sustainable sourcing. These efforts have led to improvements in consumer trust, brand reputation, and staff engagement.

This reflects a broader shift towards transparency and sustainability that aligns with global consumer expectations.

Consumer Preferences
The survey indicates that price, the 4Cs (carat, cut, colour, clarity), and certification are the primary considerations for consumers when purchasing natural diamonds. Rings remain the best-selling products, with a significant preference for diamonds weighing between 0.5 and 1 carat and priced around HK$25,000.

Consumers prioritize simplicity and emotional resonance in their jewellery choices. Social media platforms, particularly Xiaohongshu, have become vital channels for engagement and discovery.

Alignment of Qualitative and Quantitative Findings
This comprehensive study involved a mixed methodology, including an online quantitative survey and in-depth qualitative interviews, to provide insights into the current status and future outlook of the market from experienced industry stakeholders. The qualitative insights gained from in-depth interviews with senior leaders of industry bodies largely align with the quantitative findings. The outlook for the market remains cautiously optimistic, with a significant portion of respondents expecting positive performance in the coming year, demonstrating resilience in the face of ongoing challenges.

– ends –

Hong Kong Natural Diamond Trade Survey Report 2025 is available to download here

Hashtag: #ADiamondisForever #NaturalDiamonds #diamonds #DeBeersGroup




The issuer is solely responsible for the content of this announcement.

About De Beers Group

Established in 1888, De Beers Group is the world’s leading diamond company with expertise in the exploration, mining, marketing and retailing of diamonds. Together with its joint venture partners, De Beers Group employs more than 20,000 people across the diamond pipeline and is the world’s largest diamond producer by value, with diamond mining operations in Botswana, Canada, Namibia and South Africa. Innovation sits at the heart of De Beers Group’s strategy as it develops a portfolio of offers that span the diamond value chain, including its jewellery houses, De Beers Jewellers and Forevermark, and other pioneering solutions such as diamond sourcing and traceability initiatives Tracr and GemFair. De Beers Group also provides leading services and technology to the diamond industry in the form of education and laboratory services via De Beers Institute of Diamonds and a wide range of diamond sorting, detection and classification technology systems via De Beers Group Ignite. De Beers Group is committed to ‘,’ a holistic and integrated approach for creating a better future – where safety, human rights and ethical integrity continue to be paramount; where communities thrive and the environment is protected; and where there are equal opportunities for all. De Beers Group is a member of the Anglo American plc group. For further information, visit .

About Diamond Federation of Hong Kong

The Diamond Federation of Hong Kong (DFHK) is a non-profit organization with the goal of upholding integrity in the diamond industry and safeguarding consumer interests through unified business practices. DFHK’s mission is to maintain Hong Kong’s reputation as the diamond hub of Asia, a world-renowned “shopping paradise,” and an “Asian world city.” To achieve this, DFHK has established close connections and collaborations with the Hong Kong Tourism Board, Consumer Council, Hong Kong Trade Development Council, and various government agencies over the years.

Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability

By
Advertorial Desk
-

SHANGHAI and HONG KONG, Oct. 20, 2025 /PRNewswire/ — Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that the latest results from the ongoing Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate [ADC]), were presented in a Poster Presentation at the European Society for Medical Oncology Congress 2025 (ESMO 2025) in Berlin, Germany.

Details of the Poster Presentation:
ATG-022 (CLDN18.2 antibody-drug conjugate)
Title: Phase I/II study of Claudin 18.2 ADC ATG-022 in patients with advanced gastric/ gastroesophageal junction cancer (CLINCH)
Abstract Number: 2907
Presentation Number: 2113P

ATG-022 and CLINCH Study Overview

  • ATG-022 is a CLDN18.2-targeted ADC with sub-nM affinity and fast internalization. Using a VC-MMAE linker-payload (DAR 4), ATG-022 has demonstrated potent activity across tumors with high, low, and ultra-low CLDN18.2 expression.
  • The ongoing Phase I/II CLINCH study consists of dose escalation and dose expansion phases. In dose escalation, patients with advanced solid tumors regardless of CLDN18.2 expression receive ATG-022 once every three weeks (0.3-3.0 mg/kg Q3W) to evaluate the safety, tolerability, and pharmacokinetics; CLDN18.2-positive (≥ IHC 1+, 1%) patients are treated at 1.8 mg/kg or 2.4 mg/kg in dose expansion to evaluate the efficacy and safety.
  • ATG-022 has been granted two Orphan Drug designations (ODDs) by the U.S. Food and Drug Administration (FDA) for the treatment of gastric cancer and pancreatic cancer, and in August 2025 obtained Breakthrough Therapy Designation from China’s National Medical Products Administration (NMPA) for treating CLDN18.2-positive, HER-2 negative unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) who have received at least two prior lines of therapy.

Key Results from the CLINCH Study

  • Efficacy Data
    • Among GC/GEJC patients with moderate/high CLDN18.2 expression (IHC 2+ > 20%), the 2.4 mg/kg dose cohort observed 1 complete response (CR), 11 partial responses (PRs) and 15 stable diseases (SDs), resulting in an objective response rate (ORR) of 40% (12/30) and a disease control rate (DCR) of 90% (27/30). The median progression-free survival (mPFS) was 6.97 months and the 12-month overall survival (OS) rate was 66.2%. In the 1.8 mg/kg dose cohort, there were 1 CR, 9 PRs, and 11 SDs, resulting in an ORR of 40% (10/25) and a DCR of 84% (21/25).
    • Among GC/GEJC patients with low/ultra low CLDN18.2 expression (IHC 2+ ≤ 20%), patients treated at the efficacious dose of 1.8-2.4 mg/kg achieved 1 CR and 5 PRs, resulting in an ORR of 33.3% (6/18) and a DCR of 50% (9/18). The patient with CR has demonstrated durable response and has been on the study for over 22 months.
    • To date, the study has observed three CRs, one from each of the three forementioned cohorts (two dose cohorts among CLDN18.2 mid/high expressors and the cohort of low/ultra low CLDN18.2 expressors). This broad-spectrum antitumor activity indicates ATG-022’s potential as a new treatment option for a broader population of patients).
  • Safety Data
    • At 2.4 mg/kg in the dose expansion, 45.8% of patients had ≥1 treatment-emergent adverse events (TEAEs), 60.4% of patients had grade ≥3 TEAEs. The most common grade ≥3 treatment-related adverse events (TRAEs, ≥5% of patients) were neutrophil count decrease (16.7%), decreased appetite (14.6%) and anaemia (8.3%).
    • In the dose-expansion phase, the 1.8 mg/kg cohort demonstrated excellent safety and tolerability, with only 13.6% of patients reporting serious TEAEs and 18.2% reporting Grade ≥3 TEAEs. The favorable safety profile of this dose level support its potential use in first-line combination regimens with chemotherapy and immune checkpoint inhibitors.
    • No ophthalmological toxicities or interstitial lung disease have been observed.

Conclusions and Outlook

  • ATG-022 demonstrated a manageable safety profile and encouraging antitumor effects in GC/GEJC adenocarcinoma patients with a broad range of CLDN18.2 expressions, thus supporting further clinical investigation in patients with variable CLDN18.2 expressions. In addition to GC/GEJC, preliminary efficacy has been observed in other non-GI tumor types which will be reported at upcoming conferences.
  • The 2.4 mg/kg cohort showed a favorable safety profile, while the 1.8 mg/kg cohort demonstrated even better safety and tolerability. These findings provide strong support for advancing ATG-022 in combination with immune checkpoint inhibitors and chemotherapy in first-line treatment settings, paving the way to significantly expand its clinical reach and commercial potential.
  • The Phase II dose expansion study of ATG-022 is going smoothly in China and Australia. In parallel, Antengene is actively preparing for combination therapy studies involving ATG-022 to further advance its clinical development.

About Antengene

Antengene Corporation Limited (“Antengene“, SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor).

Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring “2+1” bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune disease, solid tumors and hematological malignancies indications.

To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor), is approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts: 
Donald Lung
E-mail: Donald.Lung@antengene.com
Mobile: +86 18420672158

PR Contacts:
Peter Qian
E-mail: Peter.Qian@antengene.com
Mobile: +86 13062747000

Save Now, Travel through March: T’way Air Announces Fall Savings to Korea

By
Advertorial Desk
-

Promo Code FLYOCT & Special Coupons for Travel through March 2026

TAIPEI, Oct. 20, 2025 /PRNewswire/ — T’way Air, Korea’s leading low-cost carrier, invites travelers to enjoy special savings through October 31 on Taiwan-Korea bookings for travel until March 28, 2026.

Save Now, Travel through March: T’way Air Announces Fall Savings to Korea
Save Now, Travel through March: T’way Air Announces Fall Savings to Korea

T’way Air currently operates seven direct flights to Korea: Songshan–Gimpo (Seoul), Taipei–Jeju, Taipei–Daegu, Taichung–Incheon (Seoul), Kaohsiung–Gimpo (Seoul), Kaohsiung–Incheon (Seoul), and Kaohsiung–Jeju. Full route maps and flight schedules are available at twayair.com.

T’way Air is offering the following offers until October 31:

  • Up to 15% Off Promo Code: enter promo code FLYOCT when booking, for travel through March 28, 2026. (actual savings may vary with the exchange rate at purchase).
  • First-Come TWD 500 Off Coupon: bookings of TWD 5,000 or more, travel through March 28, 2026; valid on Taipei–Jeju, and Kaohsiung–Jeju
  • TWD 300 Off Coupon: bookings of TWD 3,000 or more, travel through March 28, 2026.
  • TWD 800 Off Coupon: bookings of TWD 7,000 or more, travel through March 28, 2026.
  • TWD 400 Early Bird Coupon: bookings of TWD 3,000 or more, travel period December 1 – March 28, 2026.
  • TWD 900 Early Bird Coupon: bookings of TWD 7,000 or more, travel period December 1 – March 28, 2026.

Start in Myeongdong for street food and nonstop shopping. Walk the fortress wall in Naksan Park for sunset views, and look over the Seoul skyline from N Seoul Tower. Then try local favorites – gimbap, naengmyeon, seollongtang, and Korean hot dog – all close to major shopping and cultural hotspots. With T’way Air flights to Korea, planning a culture-rich trip is easy, and the Korean Wave adds to the fun. For a change of pace, head to Jeju Island for coastal trails and a relaxed vibe beloved by locals.

For full flight schedules, coupon terms, and booking details, visit twayair.com. T’way Air currently serves 60 destinations worldwide and continues to expand its network.

About T’way Air

T’way Air Co., Ltd., headquartered in Daegu, South Korea, is a leading low-cost carrier (LCC) providing affordable and reliable air travel since 2010. T’way Air serves customers across East Asia, Southeast Asia, Central Asia, Oceania, and Europe with a modern fleet of Boeing 737-800s, 737 MAX 8s, and Airbus A330-300, A330-200, and Boeing 777-300ERs. T’way Air continues to expand its global network, offering great value to passengers worldwide. For more information, please visit www.twayair.com.

Media Contact

T’WAY AIR Public Relations

twaypr@twayair.com

China’s enduring commitment to peaceful development: a consistent path across past, present, and future

By
Advertorial Desk
-

BEIJING, Oct. 20, 2025 /PRNewswire/ — A report from People’s Daily:

Amid a turbulent and rapidly evolving global landscape, one principle remains consistent in China’s international engagement: its unwavering commitment to peaceful development. This steadfast approach continues to position China as a stabilizing force for global peace and progress.

China recently hosted the largest-ever Shanghai Cooperation Organization (SCO) summit in history and put forward the Global Governance Initiative, reinforcing its support for more inclusive and effective international systems.

The country solemnly commemorated the 80th anniversary of the victory in the Chinese People’s War of Resistance Against Japanese Aggression and the World Anti-Fascist War, joining the international community in remembering history and safeguarding peace.

Simultaneously, China has advanced cooperation through platforms such as BRICS and the United Nations, announced new nationally determined contributions at the UN Climate Change Summit, and launched fresh initiatives to support global women ‘s development at the Global Leaders’ Meeting on Women.

China not only firmly follows the path of peaceful development but also actively contributes to global stability and positive momentum for peace and development.

The pursuit of peace and development is deeply rooted in Chinese civilization, which has long valued harmony and aspired for universal peace. Despite enduring a century of national humiliation, China emerged with a strengthened resolve to safeguard peace, not to pursue aggression or dominance.

History affirms that peaceful development is not only a national choice but a universal truth. The enduring aspirations of humanity for peace, development, fairness, justice, democracy, and freedom continue to guide collective progress. Even in times of disruption, history shows that solidarity enables the international community to restore and advance its course.

In today’s uncertain international environment, the call for peace and development remains both morally imperative and globally supported. The historical trend toward building a community of shared future for humanity remains firmly on track.

Looking ahead, China remains firmly committed to its path of peaceful development, while actively contributing to global peace and development.

China’s role in promoting peace and development is evident in its commitment to shared growth. Recently, China announced at the UN headquarters in New York that it will not seek any new special and differential treatment in current and future WTO negotiations. This solemn decision demonstrates its commitment to upholding the multilateral trading system and its sincere desire to promote common development.

China also addresses global security challenges through tangible actions. From active participation in UN peacekeeping missions to successfully facilitating the Saudi Arabia–Iran rapprochement, and consistently advocating political resolutions to the Ukraine and Palestinian-Israeli conflicts, China demonstrates its firm commitment to international peace.

Equally important is China’s embrace of dialogue and mutual learning among civilizations. This year, the first International Day for Dialogue among Civilizations was marked by themed events held simultaneously in New York, Geneva, Vienna, Nairobi, Paris, Bangkok, and The Hague. China has also hosted the Global Civilizations Dialogue Ministerial Meeting, the fourth Dialogue on Exchanges and Mutual Learning among Civilizations, and the Beijing Culture Forum. Together, these platforms have fostered understanding, cooperation, and peaceful exchange among nations.

Moreover, China contributes to global governance reform by advocating for a system based on sovereign equality rather than hegemonic dominance. The Global Governance Initiative proposed by China aims to build a more just and equitable global governance system and provide a solid foundation for sustained global peace and development.

Chinese modernization follows the path of peaceful development. China will continue to serve as a force for global peace, stability and progress. Looking ahead, if all nations uphold peaceful development, cooperate to safeguard global stability, and work together toward building a community with a shared future for humanity, the collective journey of humanity will advance toward a brighter and more promising future.

CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025

By
Advertorial Desk
-

SHANGHAI, Oct. 20, 2025 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the research results of the Phase Ib registrational clinical trial of satricabtagene autoleucel (“satri-cel”, CT041) (an autologous CAR T-cell product candidate against protein Claudin18.2) for pancreatic cancer (PC) adjuvant therapy in China (CT041-ST-05, NCT05911217) has been presented in poster session at European Society for Medical Oncology (ESMO) Congress 2025. The poster was titled “Adjuvant Therapy with Claudin18.2-specific CAR T Cells (Satri-cel) in High-Risk Pancreatic Cancer (CT041-ST-05)” (Poster number: 2220P). The trial represents the world’s first proof-of-concept (POC) study exploring CAR T-cell therapy for the adjuvant treatment of solid tumors. Professor Xianjun Yu from Fudan University Shanghai Cancer Center serves as the principal investigator.

Pancreatic ductal adenocarcinoma (PDAC) is characterized by a dismal prognosis even among patients who undergo surgical resection. Local recurrence and distant metastasis are common, often leading to treatment failure. Elevated carbohydrate antigen 19-9 (CA19-9) levels post resection indicate aggressive tumor biology and higher risk of recurrence. The median interval is approximately 3 months between CA19-9 elevation and radiological recurrence. [1][2] Current standard adjuvant therapies have limited effectiveness for high-risk patients, highlighting the urgent need for novel strategies.

This trial enrolled patients with Claudin18.2 positive PDAC who have undergone curative-intent resection, with abnormal CA19-9 after 3 months adjuvant chemotherapy and no evidence of recurrence. From Sep 15, 2023 to April 11, 2025 (data cut-off date), six patients received satri-cel infusion and completed at least 4 weeks of follow-up.

With a median follow-up of 6.05 months from infusion, only one patient experienced disease recurrence, while others are still under disease free. The median disease-free survival (DFS) and median overall survival (OS) were not reached (NR). The 9-month DFS rate from surgery was 83.3%. Notably, one patient who has completed 52-week follow-up post infusion is still under follow-up without disease recurrence. Moreover, significant decline in CA19-9 levels post infusion was observed in five (83.3%) patients, with reductions ranging from 51.3% to 96.1%.

All patients developed Grade 1 or 2 cytokine release syndrome (CRS) after the first satri-cel infusion. For the second infusion administered in one patient, grade 3 CRS accompanied by hypotension was observed, which was resolved within three days following tocilizumab treatment. All patients experienced gastrointestinal disorders, such as nausea and vomiting, which were all Grade 1 or 2. Only one case of Grade 3 gastritis occurred. No immune effector cell-associated neurotoxicity syndrome (ICANS) was reported.

Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics, said, “We are pleased to see that satri-cel has shown promising preliminary efficacy with a manageable safety profile in the highly challenging setting of pancreatic cancer adjuvant therapy. For patients at high risk of recurrence after surgical resection of pancreatic cancer, there are currently very few effective treatment options. In this trial, the sustained disease-free survival and marked declines in CA19-9 levels suggest that satri-cel, an innovative cellular immunotherapy, may clear minimal residual disease and potentially alter the disease course for these patients. Furthermore, we are actively advancing clinical trials exploring satri-cel for gastric cancer adjuvant therapy and as a sequential treatment following first-line gastric cancer therapy, with the goal of providing better curative opportunities for a broader patient population.”

About Satri-cel
Satri-cel is an autologous CAR T-cell product candidate against the protein Claudin18.2 that has the potential to be the first-in-class globally. Satri-cel targets the treatment of Claudin18.2-positive solid tumors with a primary focus on gastric/gastroesophageal junction adenocarcinoma (G/GEJA) and pancreatic cancer (PC). Initiated trials include investigator-initiated trials (CT041-CG4006, NCT03874897), a confirmatory Phase II clinical trial for advanced G/GEJA in China (CT041-ST-01, NCT04581473), a Phase Ib registrational trial for PC adjuvant therapy in China (CT041-ST-05, NCT05911217), an investigator-initiated trial for satri-cel be used as consolidation treatment following adjuvant therapy in patients with resected G/GEJA (CT041-CG4010, NCT06857786), an investigator-initiated trial for satri-cel as a sequential therapy following first-line treatment in patients with advanced G/GEJA (CT041-CG4011, NCT07179484), and a Phase 1b/2 clinical trial for advanced gastric or pancreatic adenocarcinoma in North America (CT041-ST-02, NCT04404595).

The Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for satri-cel for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy on June 25, 2025. It has been granted Priority Review in May 2025 and Breakthrough Therapy Designation in March 2025 by the CDE. Satri-cel was granted Regenerative Medicine Advanced Therapy designation by U.S. FDA for the treatment of advanced G/GEJA with Claudin18.2-positive tumors in January 2022. Satri-cel received Orphan Drug designation from the U.S. FDA for the treatment of G/GEJA in September 2020.

About CARsgen Therapeutics Holdings Limited
CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen’s mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.

Forward-looking Statements
All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group’s current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group’s control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading “Principal Risks and Uncertainties” in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.

References

[1] Pancreatology. 2019 Mar;19(2):302-306.

[2] Sci Rep. 2020 Jan 28;10(1):1332.

 

Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity

By
Advertorial Desk
-

–          The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 in 65 participants with obesity or overweight.

–          The ultra-long-acting SQ depot treatment formulation of small molecule ASC30 demonstrated a 46-day observed half-life in participants with obesity in the Phase Ib study, supporting once-monthly administration.

–          Topline data from the 12-week Phase IIa study of ASC30 once-monthly SQ depot treatment formulation are expected in the first quarter of 2026.

–          The Company will host a conference call in Mandarin today at 10:00 a.m. China Standard Time. 

HONG KONG, Oct. 20, 2025 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces the recent completion of enrollment in the U.S. Phase IIa study for its once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 for the treatment of obesity (NCT06679959). All 65 participants are obese or overweight with at least one weight-related comorbidity.

The Phase IIa study of ASC30 once-monthly SQ depot treatment formulation is a 12-week, randomized, double-blind, placebo-controlled and multi-center study conducted in the U.S. to evaluate the safety, tolerability and efficacy in participants with obesity (body mass index (BMI) ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2 but < 30 kg/m2) with at least one weight-related comorbidity. The study consists of three cohorts of different doses, with a total of 65 participants. Topline data are expected in the first quarter of 2026.

The ultra-long-acting SQ depot treatment formulation of small molecule ASC30 demonstrated a 46-day observed half-life (as measured by time to 50% Cmax) in participants with obesity in the Phase Ib study (NCT06679959), supporting once-monthly administration. ASC30 treatment formulation’s terminal half-life was 36 days.

Furthermore, the U.S. Phase Ib single ascending dose (SAD) study demonstrated that compared to the trough concentration of ASC30 at Day 29, the ultra-long-acting SQ depot treatment formulation showed a peak-to-trough ratio of approximately 1.5 to 1. The proprietary SQ depot slow-release treatment formulation of ASC30 was developed from Ascletis’ Ultra-Long-Acting Platform (ULAP). Ascletis’ ULAP technology does not have the limitations of albumin-dependent half-life extension technology, currently being applied to many peptide drugs and candidates, which limits half-life extension to the half-life of albumin (approximately 20 days).

“Completing enrollment in this study is an important milestone, marking significant progress in our development of this innovative therapy,” said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, “Ascletis’ proprietary ultra-long-acting SQ depot treatment formulation of ASC30, with its 46-day observed half-life and favorable peak-to-trough ratio of approximately 1.5 to 1, demonstrated the potential to become a once-monthly treatment option for obesity. We are looking forward to topline data from this Phase IIa study in the first quarter of 2026.”

ASC30 was discovered and developed in-house at Ascletis as a first and only investigational small molecule GLP-1R biased agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management.

Conference Call

Ascletis will host a conference call in Mandarin today, October 20, 2025 at 10:00 a.m. China Standard Time. A live webcast of the call will be available via Tecent Meeting/ VooV Meeting, with the Meeting ID: 216-282-339, or access links of:

Chinese Mainland [1]: https://meeting.tencent.com/dm/8LbPT9Fs9HoW; or
International: https://voovmeeting.com/dm/8LbPT9Fs9HoW.

[1] Chinese Mainland: the People’s Republic of China, excluding, for the purpose of this press release, Hong Kong, Macau Special Administrative Region and Taiwan, China. 

About ASC30

ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection administrations. ASC30 is a new chemical entity (NCE), with U.S. and global compound patent protection until 2044 without patent extensions. 

About Ascletis Pharma Inc.

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies, Ascletis has developed multiple drug candidates in-house, including its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).

For more information, please visit www.ascletis.com.

Contact：

Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
Peter.vozzo@icrhealthcare.com

Ascletis Pharma Inc. PR and IR teams
+86-181-0650-9129 (China)
pr@ascletis.com
ir@ascletis.com

ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)

By
Advertorial Desk
-

SUZHOU, China, Oct. 20, 2025 /PRNewswire/ — CStone Pharmaceuticals (“CStone,” HKEX: 2616),  an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, today announced the first disclosure of preliminary Phase I data for CS2009 (a PD-1/VEGF/CTLA-4 trispecific antibody) and the Phase Ib study design for CS5001 (a ROR1-targeted Antibody-Drug Conjugate [ADC]) at the 2025 European Society for Medical Oncology (ESMO) Annual Congress.

Key Highlights of CS2009 Poster Presentation:

This also represents the first known clinical data publication of a PD-1/VEGF/CTLA-4 trispecific antibody to date.

CS2009-101 is a multi-regional phase Ⅰ study currently ongoing in Australia and China. The study evaluates the safety, tolerability, pharmacokinetics (PK)/ pharmacodynamics (PD), and antitumor activity of CS2009 in patients with advanced solid tumors.

Patients baseline characteristics:

  1. As of the data cutoff date, 72 patients with advanced solid tumors treated across 6 dose levels (DL1-6, 1-45 mg/kg); 72.2% remain on treatment.
  2. Heavily pretreated population: over 51% received prior immuno-oncology (IO) therapies. Median follow-up: only 1.9 months (range 0.1-6.7 months) at data cutoff.

Favorable safety and tolerability:

  1. Dose escalation completed with no dose-limiting toxicity (DLT) reported; maximum tolerated dose (MTD) not reached.
  2. No Grade 4 or 5 treatment-related adverse event (TRAE) observed. Incidence of Grade ≥3 TRAEs, immune-related AEs (irAEs), and VEGF-related TRAEs was 13.9%, 4.2%, and 2.8%, respectively.
  3. Only 1 treatment-emergent adverse event (TEAE) leading to drug permanent discontinuation observed (at DL4 [20 mg/kg]; 1.4% incidence).

Promising antitumor activity and high disease control rate (DCR):

CS2009 demonstrated encouraging anti-tumor activities across tumor types. As of the cutoff date, the overall follow-up duration remained limited, particularly in higher-dose cohorts where the majority patients had yet to reach the protocol-specified time point of post-baseline tumor assessment:

  1. 49/72 patients underwent at least one post-baseline tumor assessment by data cutoff.
  2. Despite limited follow-up duration, anti-tumor activity was observed across all dose levels with dose-dependent uptrend:
    • Among all 49 evaluable patients, overall response rate (ORR) was 12.2%; DCR was 71.4%. Efficacy data remains immature; with additional follow-up beyond the poster data cutoff, ORR was further improved to 14.3%.
    • Higher ORR (25.0%) at tentative recommended Phase 2 dose (RP2D, 30 mg/kg) and higher dose.
  3. Promising efficacy signals were observed across multiple tumor types within the short follow-up period:
    • Non-Small Cell Lung Cancer (NSCLC): ORR: 11.8%, DCR: 82.4%; Post-ESMO update: stable disease (SD)-to-partial response (PR) conversion observed, ORR further elevated to 17.6%; In AGA-negative subgroup, ORR reached 25%;
    • Ovarian Cancer (OC): ORR: 16.7%, DCR: 66.7%;
    • Triple-Negative Breast Cancer (TNBC): ORR: 25.0%, DCR: 75.0%;
    • Non–Clear Cell Renal Cell Carcinoma (nccRCC): ORR: 33.3%, DCR: 100.0%;
    • Soft Tissue Sarcoma (STS): ORR: 11.1%, DCR: 66.7%.

Favorable PK and PD profiles:

  1. Linear PK with half-life of 6-8 days supported every-three-week (Q3W) dosing, with no significant accumulation observed at cycle 3.
  2. PD profile demonstrated saturated receptor occupancy and robust T-cell activation/proliferation confirming PD-1/CTLA-4 blockade and deep and sustained VEGFA neutralization.
    • Receptor occupancy of PD-1/CTLA-4 on peripheral T cells reached saturation throughout dosing interval at doses ≥20 mg/kg.
    • On cycle 1 day 8, CS2009 induced notable, dose-dependent upregulation of Ki67 (proliferation due to PD-1 and CTLA-4 blockade) and ICOS (activation due to CTLA-4 blockade) expression on both CD4+ and CD8+ T cells, collectively demonstrating effective PD-1 and CTLA-4 inhibition.
    • Serum-free VEGFA reduced deeply and rapidly across all dose levels, and the effect sustained throughout dose intervals.

CStone has initiated PhaseⅡdose expansion study in first-line patients with selected tumor types for dose optimization and to generate data supporting registration trials in first-line NSCLC and other tumors as monotherapy or in combination therapies.

CS2009 Data Review Conference Call:

CStone will host an investor meeting to discuss presented data and future clinical development plan. The Company cordially invites all investors to attend this conference call.

Chinese-language session:

  • Date & Time: Monday, October 20, 2025, at 2:00 p.m. (Beijing Time)/2:00 a.m. (US Eastern Time)
  • Registration Link: Registration is required, please sign up via the link: https://s.comein.cn/iq2y9krs

English-language session:

Key Highlights of CS5001 ePoster Presentation:

  1. CS5001 phase Ib study aims to determine the RP2D and further evaluate the safety, tolerability, PK, and efficacy of CS5001 as a monotherapy and in combination with systemic therapies in selected tumor types.
  2. In monotherapy cohorts, Cohorts A-D enroll patients with chronic lymphocytic leukemia and other B-cell lymphomas, and Cohort I enrolls patients with ROR1-positive solid tumors. In combination therapy cohorts (E-H), CS5001 will be administered with standard systemic therapies (R-GemOx, R2 or R-CHOP) or with sugemalimab (an anti-PD-L1 monoclonal antibody). 
  3. Patient enrollment for CS5001 Phase Ib study commenced in December 2024 and is currently advancing smoothly at 30 sites across Australia, the United States, and China.

About CStone

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas. Dedicated to addressing patients’ unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 16 new drug applications covering 9 indications. The company’s pipeline is balanced by 16 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization.

For more information about CStone, please visit: www.cstonepharma.com.

Forward-looking statements

The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.

Disclaimer: only for communication and scientific use by medical and health professionals, it is not intended for promotional purposes.

1...1,9291,9301,931...6,308Page 1,930 of 6,308